-
公开(公告)号：EP3354726B1
公开(公告)日：2024-10-30
申请号：EP17208517.7
申请日：2016-04-25
-
公开(公告)号：EP4389152A1
公开(公告)日：2024-06-26
申请号：EP22216669.6
申请日：2022-12-23
申请人： Synaffix B.V.
CPC分类号： A61K47/6851 , A61K47/6889 , A61K47/68035
摘要： The inventions concerns conjugates of masked PBD dimers, which are suitable in the treatment of cancers. The inventors found that coupling a masked PBD dimer via a glycan of a cell-binding agent increases the efficiency and tolerability of a PBD-payload. These findings allow for more effective cancer treatment with less adverse side-effects. The invention therefore concerns a conjugate of structure (1):
AB-[L-(D)x]y (1)
wherein AB is a cell-binding agent; x is 1 or 2; y is 1 or 2; D is a masked PBD dimer payload; and L is a linker that connects AB with D.-
公开(公告)号：EP2935611B1
公开(公告)日：2021-07-07
申请号：EP14790777.8
申请日：2014-10-14
-
公开(公告)号：EP2894142B1
公开(公告)日：2019-06-12
申请号：EP14191257.6
申请日：2011-04-26
申请人： SynAffix B.V.
IPC分类号： C07C33/16 , C07C69/96 , A61K49/00 , G01N33/532 , G01N33/58
-
公开(公告)号：EP3134128B1
公开(公告)日：2019-06-05
申请号：EP15813594.7
申请日：2015-10-05
申请人： Synaffix B.V.
发明人： VERKADE, Jorge Merijn Mathieu , WIJDEVEN, Maria Antonia , VAN DE SANDE, Petrus Josephus Jacobus Maria , VAN BERKEL, Sander Sebastiaan , VAN DELFT, Floris Louis
IPC分类号： A61K47/68
-
6.发明公开GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION 审中-公开BY糖生产抗体抗体结合物和方法及其
公开(公告)号：EP3057618A1
公开(公告)日：2016-08-24
申请号：EP14790776.0
申请日：2014-10-14
申请人： SynAffix B.V.
发明人： VAN DELFT, Floris Louis , VAN GEEL, Remon , WIJDEVEN, Maria Antonia , VERKADE, Jorge Merijn Mathieu , HEESBEEN, Ryan
CPC分类号： A61K47/48584 , A61K47/48384 , A61K47/48438 , A61K47/48561 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6855 , A61K47/6863 , C07K16/2863 , C07K16/32 , C07K2317/41 , C07K2317/73
摘要： The invention relates to glycoengineered antibodies and antibody-conjugates. In particular, the invention relates to an antibody conjugate, prepared from IgG antibody comprising at least two N-linked glycosylation sites on the combination of a single heavy chain and single light chain. The invention further relates to methods for the preparation of the antibody- conjugates according to the invention.In particular, the invention relates to an antibody-drug conjugate that is conjugated to different toxins, and the a process for the preparation thereof.
摘要翻译： 本发明涉及糖基化改造的抗体和抗体 - 缀合物。 特别地，本发明涉及在抗体缀合物，从IgG抗体制备包括在一个单一的重链和单轻链的组合中的至少两个N-连接糖基化位点。 本发明还涉及一种用于gemäß到本发明的抗体偶联物的制备方法。 特别地，本发明涉及对抗体 - 药物偶联物也被缀合到不同的毒素，和其制备的方法。
-
公开(公告)号：EP3057618B1
公开(公告)日：2022-12-14
申请号：EP14790776.0
申请日：2014-10-14
-
公开(公告)号：EP3177633B1
公开(公告)日：2022-07-20
申请号：EP15770973.4
申请日：2015-08-04
-
公开(公告)号：EP3733209A1
公开(公告)日：2020-11-04
申请号：EP20164714.6
申请日：2015-10-05
申请人： Synaffix B.V.
发明人： Verkade, Jorge Merijn Mathieu , Wijdeven, Maria Antonia , van de Sande, Petrus Josephus Jacobus Maria , van Berkel, Sander Sebastiaan , van Delft, Floris Louis
摘要： The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q 1 capable of reacting with a functional group F 1 present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof:
Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q 1 of a linker-conjugate according to the invention with a functional group F 1 of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention.-
公开(公告)号：EP3335733A1
公开(公告)日：2018-06-20
申请号：EP17201445.8
申请日：2013-10-23
申请人： SynAffix B.V.
IPC分类号： A61K47/68
CPC分类号： C07K16/3015 , A61K47/61 , A61K47/65 , A61K47/68 , A61K47/6803 , A61K47/6809 , A61K47/6845 , A61K47/6849 , A61K47/6855 , A61K47/6869 , A61K47/6889 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K2317/41 , C07K2317/94 , C12P21/02
摘要： The present invention relates to an antibody comprising a GlcNAc-S(A) x substituent, wherein S(A) x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A) x substituent is bonded to the antibody via C1 of the N-acetylglucosamine of said GlcNAc-S(A) x substituent, and wherein said N-acetylglucosamine is optionally fucosylated.
The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula ( 20 ) or ( 20b ), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1).
The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.
In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.03 秒)
